[Pharmacoeconomics and outcome research on Irritable Bowel Syndrome review of findings using Tegaserod].
Irritable Bowel Syndrome (IBS) is a chronic and episodic disease that affects 14.5% of females in the United States, and its impact decreases the quality of life. On the other hand, IBS consumes a great part of the health budget and develops indirect costs by loss of work productivity. Currently Tagaserod an agonist of the number 4 serotonin receptors (5-HT4), indicated for IBS-Constipation treatment, has demonstrated savings while optimizing health resources and improving the quality of life of patients and their work productivity.
Ariza
Juan Guillermo
JG
Universidad de la Sabana.
Martínez
Jairo Andrés
JA
D006801:Humans; D007211:Indoles / Q000191:economics* / Q000627:therapeutic use*; D043183:Irritable Bowel Syndrome / Q000188:drug therapy* / Q000191:economics*; D017366:Serotonin Receptor Agonists / Q000191:economics* / Q000627:therapeutic use*; D016896:Treatment Outcome
D007211:Indoles; D017366:Serotonin Receptor Agonists; C105050:tegaserod